Introduction
Although the frequency of gastric cancer varies by region, it is the fourth most common cancer in the world and the second most common cancer leading to death [1, 2] . Gastric cancer metastasizes via hematogenous and lymphogenous routes, peritoneal seeding and direct invasion. The liver, peritoneal surfaces and regional or distant lymph nodes are the most common metastatic sites. Metastasis occurs less frequently in the central nervous system, bones, lungs, soft tissues, and ovaries [3] . Metastases of mucin-secreting signet ring cell cancer (SRCC) to ovarian tissues are referred to as Krukenberg tumors, which may also originate from cancers of the colon, appendix, and breasts [4] . These tumors are rare, accounting for 1-2% of all ovarian cancers [4, 5] .
Here, we analyzed the characteristics, treatment modalities, and prognosis, including progression-free survival (PFS) and overall survival (OS), of patients with Krukenberg tumors that originated from gastric cancer.
Material and methods
The medical records of patients who were diagnosed with gastric cancer and who underwent follow-up and treatment in the Ankara Oncology Education and Research Hospital between January 2005 and January 2012 were evaluated retrospectively, and patients with histopathologically identified ovarian metastasis were enrolled in the study. All cancers other than ovarian metastases of gastric origin were excluded from the study. For each enrolled patient, the age, Eastern Cooperative Oncology Group (ECOG) performance status, menopausal status, complaints, date of histopathological diagnosis of the primary tumor, treatment modalities after diagnosis (surgery, radiotherapy, and chemotherapy), date of histopathological diagnosis of ovarian metastasis, diagnostic methods, and final follow-up date were recorded. The median OS and PFS were calculated.
The data were analyzed using SPSS for Windows, version 11.5.
Results
Among 1755 patients diagnosed with gastric cancer between January 2005 and January 2012 at the Ankara Oncology Education and Research Hospital, eight patients (0.45%) with histopathologically identified Krukenberg tumors were enrolled. Radiological findings of a patient are presented in Fig. 1 and Fig. 2 . Their median age was 42.2 years (range, 32-69 years); seven (87.5%) were premenopausal, and one (12.5%) was post-menopausal. The performance status was ECOG 1 in seven (87.5%) patients and ECOG 2 in one patient (12.5%). Upon admission, four (50%) of the patients had abdominal pain, three (37.5%) had abdominal swelling, and one (12.5%) had complaints of nausea and vomiting. One patient (12.5%) had adenocarcinoma and SRCC, two (25%) had adenocarcinoma, and five (62.5%) had SRCC based on histopathological examinations of the specimens of gasters. Four (50%) of the patients underwent surgery (distal subtotal gastrectomy in two; total gastrectomy in two). The primary tumors in the other four patients were considered to be inoperable. At the time of diagnosis, two patients (25%) were stage 3A, two (25%) were stage 3C, and four (50%) were stage 4. Ovarian metastasis was diagnosed by ovarian biopsy in three patients (37.5%), by unilateral salpingo-oophorectomy in three patients (37.5%), and by bilateral salpingo-oophorectomy in two patients (25%). Histopathological examinations of ovaries in all patients were reported as SRCC. The four patients with a stage 3 diagnosis were treated with the protocol described by Macdonald et al. [6] . This protocol is defined as [7] . In one patient who was diagnosed with SRCC after a right oophorectomy, the primary tumor could not be found at the time of the evaluation, which included gastroscopy; she was thought to have primary ovarian SRCC and received carboplatin/paclitaxel chemotherapy. When she was evaluated for tumor response after three cycles of chemotherapy, computed tomography of the abdomen revealed thickening of the wall of the stomach, and she was diagnosed with gastric cancer after a second gastroscopy. The remaining patient was unable to undergo chemotherapy due to acute renal failure.
The median PFS was 13.2 months (range, 1-25 months), the median OS after the original diagnosis was 16.7 months (range, 1-41 months), and the median OS after ovarian metastasis was 3.6 months (range, 1-10 months). The survival time was longest for the patients who were stage 3A at the time of diagnosis and underwent bilateral salpingo-oophorectomy after developing ovarian metastasis (Table 1) .
Discussion
Gastric cancer occurs mainly in people between the ages of 50 and 70 [8] . Gastric SRCC is less common than adenocarcinoma, with previous studies reporting incidences between 3.4% and 15.1% [9] [10] [11] [12] [13] . Deep invasion, lymph node involvement, and peritoneal metastasis are more frequent in gastric SRCC compared with other subtypes of gastric cancer, and its prognosis is worse [14] . Gastric SRCC is more infiltrative, with greater affinity for lymphatic tissue and a higher rate of peritoneal carcinomatosis, compared with the reported prognosis of gastric adenocarcinoma. Therefore, extended lymph node dissection and curative surgery are recommended for this histological type [10, 11, 13] .
Ovarian metastasis of gastric cancer was first observed by Friedrich Ernst Krukenberg in 1896. Previously, all metastatic ovarian cancers had been referred to as Krukenberg tumors; however, Novak and Gray created new diagnostic criteria to eliminate any confusion. Accordingly, a mucin-secreting SRCC tumor in the dense fibroblastic stroma of the ovary is referred to as a Krukenberg tumor [15] . Primary SRCC of the ovaries and Krukenberg tumors may morphologically resemble one another, making the differential diagnosis difficult. Immunohistochemical evaluation can be beneficial in differentiating between primary ovarian cancers and metastatic ovarian cancers. Cytokeratin (CK)7 negative/CK20 positive or CK7 positive/CK20 positive immunophenotype (CK20 positivity, in particular) is used in the diagnosis of metastatic gastrointestinal cancer. Furthermore, positive staining for the gastric mucin gene MUC5AC is important in the diagnosis of metastatic gastric cancer over primary ovarian adenocarcinoma [16] . Nevertheless, it is important to clinically distinguish these tumors because of the significant differences in their treatment protocols, chemotherapy response, and prognosis [17] . There are some cases in the literature in which an initially diagnosed metastatic carcinoma of the ovary was subsequently, upon further investigation, understood to have been early gastric cancer. In cases with an early-stage primary tumor, lymphatic invasion may be the most likely way of metastasis. In the present series, one case that had been accepted and treated as a primary ovarian tumor when a mass was detected in the ovarian tissue was found not to be a primary ovarian tumor after further investigation. Instead, after three cycles of chemotherapy, the primary tumor was identified as gastric cancer [18] [19] [20] . A Krukenberg tumor can vary in terms of its depth and the number of metastatic lymph nodes derived from the primary tumor, and these factors influence survival [21, 22] .
Surgery is the main treatment in the absence of metastases for medically fit patients. However, considering local and distant recurrence of gastric cancer, chemotherapy and radiation therapy are also included [23] . Postoperative chemoradiotherapy is shown to decrease local recurrence in patients with locally advanced gastric cancer. Progression-free survival and OS data demonstrate a continued strong benefit from postoperative chemoradiotherapy [6, 24, 25] . Palliative options including radiotherapy may be applied for unresectable, or metastatic gastric cancer [23, 26] . [27] . The DCF chemotherapy protocol significantly improved PFS, OS, and response rate in gastric cancer patients [7] . Despite the development of chemotherapeutic agents for treating metastatic disease, the prognosis is usually poor, with a 5-year survival rate of 5-15% [28] .
Chemotherapy is currently the standard treatment for advanced gastric cancer, but the efficacy of metastasectomy is under investigation. In a study of metastasectomy for liver metastasis, which is one of the most common organ metastases of gastric cancer, survival was prolonged when there was no peritoneal dissemination and there were fewer than two liver metastases [29] . Another study showed that serosal invasion and liver tumor size greater than 5 cm were indicators of a poor prognosis [30] .
Several studies have evaluated the effectiveness of metastasectomy for ovarian metastasis of gastric cancer. In patients with Krukenberg tumors originating from the stomach, overall survival times were 14.1 and 8 months for patients who did and did not undergo metastasectomy, respectively, indicating that metastasectomy improves survival [31] . In another study, patients with primary gastric tumors resulting in Krukenberg tumors and who underwent metastasectomy had a survival time of 18.8 months, and the 3-year survival rate was 15.8%; the most important factors affecting survival were early diagnosis and resection of the tumor [32] .
Ovarian metastasis of gastric cancer is not common. However, gastric SRCC occurs most frequently in young women during the premenopausal period. When the only metastatic site is the ovary, metastasectomy can prolong survival time.
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